{"product_id":"humanwell-business-model-canvas","title":"Humanwell Healthcare Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumanwell Healthcare: Actionable Business Model Canvas for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Humanwell Healthcare’s business model—this in-depth Business Model Canvas reveals how the company creates value, scales revenue streams, and leverages partnerships to stay competitive; ideal for investors, consultants, and founders seeking actionable, ready-to-use insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumanwell partners with top universities and global institutes (including 2024 collaborations with Peking University and Karolinska Institutet) to convert neuroscience and anesthetic research into its clinical pipeline, shortening preclinical timelines by about 18% and cutting early-stage failure costs an estimated ¥120–200M per program. These ties lower development risk, provide access to specialized assays and talent, and helped Humanwell advance three CNS candidates into Phase I\/II by end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumanwell maintains alliances with top Chinese hospital groups—over 120 tertiary hospitals as of 2025—to run clinical trials and collect real-world evidence, supporting 18 formulary listings secured in 2024 alone.\u003c\/p\u003e\n\u003cp\u003eThese networks deliver clinician feedback that shaped three product iterations in 2023–25 and helped reduce time-to-market by an estimated 14%, aligning drugs with provider needs and payer requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHumanwell Healthcare partners with established logistics and distribution firms in North America and Africa—adding warehousing, cold chain and regulatory compliance—to target a 15–20% revenue share from overseas markets by 2026; in 2024 export-related sales rose ~12% to CNY 1.3bn (≈USD 180m). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHumanwell maintains long-term contracts with API and raw-material suppliers to secure continuous supply of high-quality inputs, cutting supply disruptions and stabilizing COGS; in 2024 suppliers covered \u0026gt;85% of API needs and helped keep gross margin near 42%.\u003c\/p\u003e\n\u003cp\u003eThese partnerships support compliance with Good Manufacturing Practice across all plants, enabling consistent product quality and reducing batch failure rates to under 1.5% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term contracts: \u0026gt;85% API coverage (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin stability: ~42% (2024)\u003c\/li\u003e\n\u003cli\u003eBatch failure rate: \u0026lt;1.5% (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: GMP compliance across facilities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Venture Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHumanwell Healthcare frequently forms joint ventures with international pharma firms to co-develop and co-market specialty medical devices and biologics, sharing R\u0026amp;D and capex to cut time-to-market by ~20% and split costs—example: a 2024 JV targeting ophthalmic biologics with €30m pooled investment.\u003c\/p\u003e\n\u003cp\u003eThese partnerships let Humanwell pool tech, access overseas channels, and diversify beyond anesthetics, raising non-anesthetic revenue share to ~28% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShared R\u0026amp;D\/capex: €30m example\u003c\/li\u003e\n\u003cli\u003eFaster launch: ~20% reduced time\u003c\/li\u003e\n\u003cli\u003e2024 non-anesthetic revenue: ~28%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumanwell partnerships slash R\u0026amp;D time\/costs, drive CNY1.3bn exports and 42% margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHumanwell’s partnerships—universities (Peking Univ., Karolinska), 120+ tertiary hospitals, long-term API suppliers (\u0026gt;85% coverage 2024), logistics partners, and JVs (€30m ophthalmic JV 2024)—cut preclinical time ~18%, lower early-stage costs ¥120–200M\/program, reduced time-to-market ~14–20%, supported CNY1.3bn export sales (2024) and 42% gross margin.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport sales\u003c\/td\u003e\n\u003ctd\u003eCNY1.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical cut\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Humanwell Healthcare covering customer segments, channels, value propositions, key activities, resources, partners, cost structure and revenue streams, reflecting real-world operations and strategic plans with SWOT-linked insights and competitive advantages for investor and internal presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Humanwell Healthcare’s business model with editable cells to quickly pinpoint value propositions, partnerships, and revenue streams as a concise pain-relief tool for strategy alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D and Drug Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumanwell focuses on continuous R\u0026amp;D in pain management and neurology, investing over CNY 1.2 billion in 2024 (≈USD 170M) across three R\u0026amp;D centers to discover new chemical entities and improve delivery mechanisms.\u003c\/p\u003e\n\u003cp\u003eThis sustained R\u0026amp;D supports a pipeline of patent-protected products—Humanwell reported 18 active clinical-stage programs and expects 3 NDA filings by 2026, underpinning long-term growth and market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumanwell runs multiple large-scale plants meeting WHO and EU GMP standards, producing chemical and biologic drugs with annual capacity \u0026gt;1.2 billion doses; production yield improvements cut waste 7% in 2024 while QA pass rates stayed \u0026gt;99.2%. Modernization to automated lines—budgeted RMB 480 million through 2025—targets 18–22% efficiency gains and faster batch release times.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Marketing and Brand Building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHumanwell runs targeted marketing to educate clinicians on its specialty drugs via medical conferences, peer-reviewed publications, and KOL (key opinion leader) programs; in 2024 the company reported ~RMB 1.2bn in R\u0026amp;D\/medical affairs spend supporting 150+ clinical presentations globally. Effective branding and real-world evidence helped lift premium product mix, contributing to a 12% YoY export revenue rise in 2024 versus generics pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHumanwell runs continuous regulatory work—documenting trials, batch testing, and stability studies—to meet NMPA (China) and FDA (US) rules; in 2024 Humanwell reported compliance-related spending of CNY 420 million (~USD 58M) to support 12 GMP-certified sites and 18 active IND\/NDA programs.\u003c\/p\u003e\n\u003cp\u003eContinuous monitoring and quarterly quality audits sustain licences for export to 45+ countries and reduce batch rejection rates to under 0.8% year-to-date.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual compliance spend: CNY 420M (~USD 58M)\u003c\/li\u003e\n\u003cli\u003eGMP sites: 12\u003c\/li\u003e\n\u003cli\u003eActive IND\/NDA programs: 18\u003c\/li\u003e\n\u003cli\u003eCountries served: 45+\u003c\/li\u003e\n\u003cli\u003eBatch rejection rate: \u0026lt;0.8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHumanwell manages a global supply chain coordinating raw-material procurement, internal logistics, and distribution to 40+ markets, using advanced analytics that cut inventory days from 120 to 85 on core respiratory and critical-care lines in 2024.\u003c\/p\u003e\n\u003cp\u003eThis lets Humanwell respond within 7–14 days to market shifts and maintain \u0026gt;98% availability for ICU products during 2024 surge periods.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal reach: 40+ markets\u003c\/li\u003e\n\u003cli\u003eInventory days: 120 → 85 (2024)\u003c\/li\u003e\n\u003cli\u003eResponse time: 7–14 days\u003c\/li\u003e\n\u003cli\u003eICU availability: \u0026gt;98% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumanwell: CNY1.2bn R\u0026amp;D, 18 trials, 12 GMP sites, \u0026gt;1.2bn doses \u0026amp; \u0026gt;99.2% QA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHumanwell runs R\u0026amp;D (CNY 1.2bn in 2024), 18 clinical programs, 3 NDAs expected by 2026; operates 12 WHO\/EU GMP sites with \u0026gt;1.2bn dose capacity, QA pass \u0026gt;99.2% and \u0026lt;0.8% rejection; cut inventory days 120→85, supplies 40–45 markets with 7–14 day response and \u0026gt;98% ICU availability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCNY 1.2bn (~USD 170M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e18 active\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.2bn doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA pass rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch rejection\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory days\u003c\/td\u003e\n\u003ctd\u003e85 (was 120)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e40–45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResponse time\u003c\/td\u003e\n\u003ctd\u003e7–14 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICU availability\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Humanwell Healthcare Business Model Canvas shown here is the actual deliverable—not a mockup—and reflects the exact structure, content, and formatting you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you’ll get this identical file ready to edit and present, provided in the same professional format with all sections included—no surprises, no placeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749737869689,"sku":"humanwell-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/humanwell-business-model-canvas.png?v=1772217723","url":"https:\/\/growthsharematrix.com\/products\/humanwell-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}